Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Counting on ubiquity

Integrin alpha(v)beta(3) has several roles, and while some could be important in inflammatory diseases, the receptor's functions are better validated in cancer. As such, MedImmune Inc. took a calculated risk when it started Phase II trials of its Vitaxin humanized monoclonal antibody against

Read the full 436 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE